Treatment for early-stage lung cancer: what next?
A partir d'une revue de la littérature publiée à partir de janvier 1965 (15 essais randomisés identifiés, 2 385 patients), cette méta-analyse évalue l'efficacité, du point de vue de la survie globale, d'une chimiothérapie pré-opératoire pour les patients atteints d'un cancer du poumon non à petites cellules
Lung cancer is the leading cause of cancer-related mortality worldwide, accounting for 19% of cancer-related deaths. 1 This devastating toll is the consequence of a high incidence (1·8 million new diagnoses in 2012) and a low rate of cure. Most patients continue to be diagnosed at advanced disease stages. Moreover, the outcome of patients who present with resectable and operable lung cancer (about 25% of cases) is substantially worse than that noted in many other early-stage solid tumours...
The Lancet , commentaire, 2013